Chicago-based Rush University Medical Center will collaborate with Tempus — a health technology company focused on personalized oncology care — to operationalize its first biobank.
The biorepository will enable researchers at the hospital to access tissue samples from across the institution. Rush and Tempus will also work together to develop 3-D organoids to test how patients may respond to specific cancer treatments.
"The collaboration we are announcing today should allow us over a very short period of time to collect thousands of bio-specimens that will be used to fuel decades of groundbreaking research," said Dr. Ranga Krishnan, senior vice president of Rush.
The agreement builds on Rush and Tempus' existing collaboration, under which Tempus provides the hospital with molecular sequencing and analysis for cancer patients.